These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Size of cancer clinical trials and stopping rules. Pocock SJ Br J Cancer; 1978 Dec; 38(6):757-66. PubMed ID: 369589 [TBL] [Abstract][Full Text] [Related]
43. [Clinical aspects of clinical comparative experiments]. Strnad L Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl; 1988; 31(4):529-42. PubMed ID: 3249937 [No Abstract] [Full Text] [Related]
44. Full disclosure in study design is essential. Lerman J Anesth Analg; 1997 Nov; 85(5):1178-9. PubMed ID: 9356126 [No Abstract] [Full Text] [Related]
45. Randomized clinical trials and research strategy. Simon R Cancer Treat Rep; 1982 May; 66(5):1083-7. PubMed ID: 7083212 [No Abstract] [Full Text] [Related]
46. Randomization and optimal design. Smith W J Chronic Dis; 1983; 36(9):609-15. PubMed ID: 6619257 [No Abstract] [Full Text] [Related]
47. Further comment on "Statistical inference from clinical trials: choosing the right P value". Canner PL Control Clin Trials; 1983 Mar; 4(1):35. PubMed ID: 6851580 [No Abstract] [Full Text] [Related]
48. Assessment of futility in clinical trials. Snapinn S; Chen MG; Jiang Q; Koutsoukos T Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426 [TBL] [Abstract][Full Text] [Related]
49. [Problems raised by interim analysis in therapeutic trials]. Rodary C; Nougue CC Bull Cancer; 1982; 69(4):387-92. PubMed ID: 7150794 [TBL] [Abstract][Full Text] [Related]
50. Application of restricted sequential design in a clinical protocol. Thompson EI Cancer Treat Rep; 1980; 64(2-3):399-403. PubMed ID: 7407776 [TBL] [Abstract][Full Text] [Related]
51. Planning multicenter clinical trials: a biostatistician's perspective. Weiss DG; Williford WO; Collins JF; Bingham SF Control Clin Trials; 1983 Mar; 4(1):53-64. PubMed ID: 6342939 [No Abstract] [Full Text] [Related]
52. Multi-institutional randomized clinical trials as a research method in cancer. Ortiz HG Int J Radiat Oncol Biol Phys; 1985 May; 11(5):1053-6. PubMed ID: 3988555 [No Abstract] [Full Text] [Related]
53. [Quality of clinical information (II): Statistical significance]. Plasencia A; Porta Serra M Med Clin (Barc); 1988 Jan; 90(3):122-6. PubMed ID: 3280891 [No Abstract] [Full Text] [Related]
54. Design and analysis issues. Coleman WP Front Neurol Neurosci; 2009; 25():114-117. PubMed ID: 19478506 [No Abstract] [Full Text] [Related]
55. When to stop a clinical trial. Neale EJ BMJ; 1992 Aug; 305(6851):475. PubMed ID: 1392974 [No Abstract] [Full Text] [Related]
56. Comments on 'Current issues in non-inferiority trials' by Thomas R. Fleming, Statistics in Medicine, DOI: 10.1002/sim.2855. Koch GG Stat Med; 2008 Feb; 27(3):333-42. PubMed ID: 17530625 [No Abstract] [Full Text] [Related]
57. [Controlled therapeutic trials: elaboration of the protocol]. Rodary M Rev Prat; 1983 Apr; 33(19):963-4, 967-8, 971-3. PubMed ID: 6867568 [No Abstract] [Full Text] [Related]
59. [The decision-making value of clinical studies]. Sámal M; Rezný Z; Maríková E; Foltýnová V; Dienstbier Z Cas Lek Cesk; 1983 Mar; 122(12):374-7. PubMed ID: 6861173 [No Abstract] [Full Text] [Related]
60. Adaptive clinical trial designs: ready for prime time? Proceedings of the Harvard-MIT Division of Health Science and Technology Workshop. October 2004. Stat Med; 2006 Oct; 25(19):3229-347. PubMed ID: 16847901 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]